Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Gross Margin of 91.63% for Q1 2026, up 3.43% on a QoQ basis from 88.59% in Q4 2025, and up 535.0% year-over-year from 14.43% in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Gross Margin history runs 7 years deep, the most recent figure standing at 91.63% for Q1 2026.
- Quarterly Gross Margin rose 535.0% year-over-year to 91.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.74% (up 150.0% YoY) and the FY2025 annual result came in at 88.46%, up 47.0% from the prior year.
- Gross Margin was 91.63% for Q1 2026 at Aurinia Pharmaceuticals, up from 88.59% in the prior quarter.
- Across five years, Gross Margin topped out at 98.82% in Q1 2022 and bottomed at 84.42% in Q2 2024.
- A 5-year average of 91.21% and a median of 90.73% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin sank 1419 bps — and 2025, when it jumped 541 bps.
- Aurinia Pharmaceuticals' Gross Margin stood at 95.21% in 2022, then retreated by 8 bps to 88.04% in 2023, then advanced by 3 bps to 90.73% in 2024, then dropped by 2 bps to 88.59% in 2025, then advanced by 3 bps to 91.63% in 2026.
- Business Quant data shows AUPH's Gross Margin at 91.63% in Q1 2026, 88.59% in Q4 2025, and 88.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 91.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.63% |
| Dec 31, 2025 | 88.59% |
| Sep 30, 2025 | 88.87% |
| Jun 30, 2025 | 89.84% |
| Mar 31, 2025 | 86.27% |
| Dec 31, 2024 | 90.73% |
| Sep 30, 2024 | 91.10% |
| Jun 30, 2024 | 84.42% |
| Mar 31, 2024 | 84.59% |
| Dec 31, 2023 | 88.04% |
| Sep 30, 2023 | 87.58% |
| Jun 30, 2023 | 96.23% |
| Mar 31, 2023 | 98.78% |
| Dec 31, 2022 | 95.21% |
| Sep 30, 2022 | 95.61% |
| Jun 30, 2022 | 94.33% |
| Mar 31, 2022 | 98.82% |
| Dec 31, 2021 | 97.94% |
| Sep 30, 2021 | 98.27% |
| Jun 30, 2021 | 95.35% |